BeyondSpring Abstract Demonstrating Bone Pain Benefit with Lead Asset, Plinabulin, versus Neulasta for Neutropenia Prevention ...
(World News USA)

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company´s abstract on its lead asset, Plinabulin, has been accepted for poster presentation at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2019 Conference. ISPOR is internationally recognized as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in healthcare decisions. ......